NuVasive Investor Relations

NuVasive is a world leader in minimally invasive, procedurally-integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes.

Press Release

NuVasive Announces First Quarter 2019 Financial Results

SAN DIEGO, May 1, 2019 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended March 31, 2019.

NuVasive Logo

First Quarter 2019 Highlights

  • Revenue increased 5.5% to $274.8 million, or 6.4% on a constant currency basis;
  • GAAP operating profit margin of 7.3%; Non-GAAP operating profit margin of 14.9%; and
  • GAAP diluted earnings per share of $0.18; Non-GAAP diluted earnings per share of $0.53.

"In the first quarter 2019, NuVasive delivered a solid start to the year with focused execution across our U.S. Spinal Hardware, U.S. Surgical Support and International businesses," said Chris Barry, chief executive officer of NuVasive. "Coupled with these financial results, we continued to operate the business with rigor and discipline to drive profitability while strategically investing in key growth areas. This includes the recently launched X360 System for lateral single-position surgery integrated with Surgical Intelligence, further differentiation of our Advanced Materials Science portfolio and upcoming launch of the Pulse platform—all which enable our surgeon partners to provide better, more reproducible clinical outcomes for their patients through minimally invasive surgery."

A full reconciliation of GAAP to non-GAAP financial measures can be found in the tables of this news release.

First Quarter 2019 Results
NuVasive reported first quarter 2019 total revenue of $274.8 million, a 5.5% increase compared to $260.5 million for the first quarter 2018. On a constant currency basis, first quarter 2019 total revenue increased 6.4% compared to the same period last year.

For the first quarter 2019, both GAAP and non-GAAP gross profit was $200.3 million and GAAP and non-GAAP gross margin was 72.9%. These results compared to GAAP and non-GAAP gross profit of $186.7 million and $187.1 million, respectively, and GAAP and non-GAAP gross margin of 71.7% and 71.8%, respectively, for the first quarter 2018.

The Company reported GAAP net income of $9.4 million, or diluted earnings per share of $0.18, for the first quarter 2019 compared to a GAAP net loss of $(27.1) million, or diluted loss per share of $(0.53), for the first quarter 2018. On a non-GAAP basis, the Company reported net income of $27.6 million, or diluted earnings per share of $0.53 per share, for the first quarter 2019 compared to net income of $20.6 million, or diluted earnings per share of $0.40 per share, for the first quarter 2018.

Annual Financial Guidance for 2019
The Company reiterated its full-year 2019 guidance:


2019 Guidance Range 1


Prior


Current


 GAAP 

 Non-GAAP 


 GAAP 

 Non-GAAP 

Revenue

 $1.14B - $1.16B 


 $1.14B - $1.16B 


 $1.14B - $1.16B 


 $1.14B - $1.16B 

  % Growth - Reported

3.5% - 5.5%


3.5% - 5.5%


3.5% - 5.5%


3.5% - 5.5%

% Growth - Constant Currency2



3.8% - 5.8%




3.8% - 5.8%

Operating margin

9.5% - 10.0%


15.0% - 15.5%


9.0% - 9.5%


15.0% - 15.5%

Earnings per share

 $1.00 - $1.10 


 $2.20 - $2.30 


 $0.95 - $1.05 


 $2.20 - $2.30 

EBITDA margin

21.2% - 21.7%


25.2% - 25.7%


20.9% - 21.3%


25.2% - 25.7%

Tax Rate

~24%


~23%


~22%


~23%


     1

Prior guidance reflects the range provided February 20, 2019. Current guidance reflects the range provided May 1, 2019.

     2

Constant currency is a measure that adjusts US GAAP revenue for the impact of currency over the same period in the prior year.

 

  • The Company estimates revenue for full year 2019 to be in the range of $1.14 billion to $1.16 billion, reflecting reported growth in the range of 3.5% to 5.5%;
  • Non-GAAP earnings per share in a range of $2.20 to $2.30;
  • Non-GAAP operating profit margin of 15.0% to 15.5%;
  • EBITDA margin of 25.2% to 25.7%; and
  • Non-GAAP effective tax expense rate of approximately 23%.

Supplementary Financial Information
For additional financial detail, please visit the Investor Relations section of the Company's website at www.nuvasive.com to access Supplementary Financial Information.

Reconciliation of Full Year EPS Guidance




2019 Guidance Range  1, 2


2018

Actuals 1


Prior 3


Current 4

GAAP net income per share

$0.24


 $1.00 - 1.10 


 $0.95 - 1.05 

Impact of change to diluted share count



GAAP net income per share, adjusted to diluted Non-GAAP share count

$0.24


 $1.00 - 1.10 


 $0.95 - 1.05 







Business transition costs 5

0.22



0.10

Non-cash purchase accounting adjustments on acquisitions 6

0.02



Non-cash interest expense on convertible notes

0.32


0.30


0.30

Litigation related expenses and settlements 7

0.65


0.20


0.20

Non-recurring consulting fees 8

0.12



Net loss on strategic investments

0.07



Amortization of intangible assets

0.97


0.90


0.95

Purchase of in-process research and development 9

0.17



European medical device regulation10

0.01


0.10


0.10

Tax effect of adjustments11

(0.56)


(0.30)


(0.40)

Non-GAAP earnings per share

$2.23


 $2.20 - 2.30 


 $2.20 - 2.30 







GAAP Weighted shares outstanding - basic

51,382


52,017


51,999

GAAP Weighted shares outstanding - diluted

52,355


52,938


52,991

Non-GAAP Weighted shares outstanding - diluted 12

52,178


52,714


52,718




1

Items may not foot due to rounding.

2

Prior guidance reflects the range provided February 20, 2019. Current guidance reflects the range provided May 1, 2019.

3

Effective tax expense rate of ~24% applied to GAAP earnings and ~23% applied to Non-GAAP earnings.

4

Effective tax expense rate of ~22% applied to GAAP earnings and ~23% applied to Non-GAAP earnings.

5

Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party merger and acquisitions costs, contingent consideration fair value adjustments, and other costs directly associated with such activities.

6

Represents costs associated with non-cash purchase accounting adjustments, such as acquired inventory fair market value adjustments, which are amortized over the period in which underlying products are sold.

7

Represents the loss recorded in connection with the settlement of the Madsen Medical, Inc. litigation matter, as well as expenses associated with ongoing litigation with a former Board member and his current employer related to various matters, including infringement of the Company's intellectual property.

8

Non-recurring consulting fees associated with the implementation of our state tax-planning strategy.

9

Purchase of an in-process research and development asset which had no future alternative use.

10

Represents costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with European medical device regulation.

11

The impact on results from taxes include tax effecting the adjustments above at the statutory rate as well as taking into account discrete items and including those discrete items in the annual effective tax rate calculation. The Company also includes those adjustments that would have benefited the tax rate in lieu of the above adjustments as part of the Company's tax filings. The impact of the changes to the tax rate results in an annual rate of ~43% benefit on a GAAP basis and ~18% on a non-GAAP basis in 2018.

12

Adjusted non-GAAP diluted WASO excludes the impact of dilutive convertible notes and warrants for which the Company is economically hedged through its anti-dilutive bond hedge arrangements.

 

Reconciliation of Non-GAAP Operating Margin %












2019 Guidance Range 1, 2

(in thousands, except %)


2018
Actuals 1


Prior


Current

Non-GAAP Gross Margin % [A]


71.9%


72.5% - 73.0%


72.5% - 73.0%

Non-cash purchase accounting adjustments on acquisitions 3


(0.1%)


0.0%


0.0%

GAAP Gross Margin [B]


71.8%


72.5% - 73.0%


72.5% - 73.0%








Non-GAAP Sales, Marketing & Administrative Expense [C]


51.1%


51.0% - 52.0%


51.0% - 52.0%

Non-recurring consulting fees4


0.6%


0.0%


0.0%

Litigation related expenses5


0.6%


0.7%


0.7%

GAAP Sales, Marketing & Administrative Expense [D]


52.3%


51.7% - 52.7%


51.7% - 52.7%








GAAP and Non-GAAP Research & Development Expense [E]


5.6%


6.0%


6.0%








Litigation related settlements [F]6


2.5%


0.0%


0.0%

Amortization of intangible assets [G]


4.6%


4.2%


4.3%

Purchase of in-process research and development [H]7


0.8%


0.0%


0.0%

European medical device regulation [I]8


0.0%


0.6%


0.6%

Business transition costs [J] 9


1.0%


0.0%


0.4%








Non-GAAP Operating Margin % [A - C - E]


15.1%


15.0% - 15.5%


15.0% - 15.5%








GAAP Operating Margin % [B - D - E - F - G - H - I - J]


4.9%


9.5% - 10.0%


9.0% - 9.5%



1

Items may not foot due to rounding.

2

Prior guidance reflects the range provided February 20, 2019. Current guidance reflects the range provided May 1, 2019.

3

Represents costs associated with non-cash purchase accounting adjustments, such as acquired inventory fair market value adjustments, which are amortized over the period in which underlying products are sold.

4

Non-recurring consulting fees associated with the implementation of our state tax-planning strategy.

5

Expenses associated with ongoing litigation with a former Board member and his current employer related to various matters, including infringement of the Company's intellectual property.

6

Represents the loss recorded in connection with the settlement of the Madsen Medical, Inc. litigation matter.

7

Purchase of an in-process research and development asset which had no future alternative use.

8

 

Represents costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with European medical device regulation.

9

Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party merger and acquisitions costs, contingent consideration fair value adjustments, and other costs directly associated with such activities.

 

Reconciliation of EBITDA Margin %










2019 Guidance Range1, 5

(in thousands, except %)

2018 Actuals 1, 2


Prior 3


Current4

Net Income

1.1%


4.6% - 5.0%


4.3% - 4.8%

Interest income / expense, net 

3.4%


3.3%


3.3%

Income tax benefit / (expense)

(0.3%)


1.5%


1.3%

Depreciation and amortization

11.8%


11.7%


12.0%

EBITDA Margin

16.0%


21.2% - 21.7%


20.9% - 21.3%

Non-cash stock based compensation

2.3%


2.7%


2.6%

Business transition costs6

1.0%


0.0%


0.4%

Non-cash purchase accounting adjustments on acquisitions7

0.1%


0.0%


0.0%

Litigation related expenses and settlements 8

3.1%


0.7%


0.7%

Non-recurring consulting fees 9

0.6%


0.0%


0.0%

In-process research and development10

0.8%


0.0%


0.0%

European medical device regulation11

0.0%


0.6%


0.6%

Net loss on strategic investments

0.3%


0.0%


0.0%

Adjusted EBITDA Margin

24.3%


25.2% - 25.7%


25.2% - 25.7%



1

Items may not foot due to rounding.

  2

Effective tax expense rate of ~43% benefit applied to GAAP earnings and ~18% applied to Non-GAAP earnings.

 3

Effective tax expense rate of ~24% applied to GAAP earnings and ~23% applied to Non-GAAP earnings.

4

Effective tax expense rate of ~22% applied to GAAP earnings and ~23% applied to Non-GAAP earnings.

5

Prior guidance reflects the range provided February 20, 2019. Current guidance reflects the range provided May 1, 2019.

6

Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party merger and acquisitions costs, contingent consideration fair value adjustments, and other costs directly associated with such activities.

7

Represents costs associated with non-cash purchase accounting adjustments, such as acquired inventory fair market value adjustments, which are amortized over the period in which underlying products are sold.

8

Represents the loss recorded in connection with the settlement of the Madsen Medical, Inc. litigation matter, as well as expenses associated with ongoing litigation with a former Board member and his current employer related to various matters, including infringement of the Company's intellectual property.

9

Non-recurring consulting fees associated with the implementation of our state tax-planning strategy.

10

Purchase of an in-process research and development asset which had no future alternative use.

11

Represents costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with European medical device regulation.

Reconciliation of Non-GAAP Information
Management uses certain non-GAAP financial measures such as non-GAAP earnings per share, non-GAAP net income, non-GAAP operating expenses and non-GAAP operating profit margin, which exclude amortization of intangible assets, business transition costs, purchased in-process research and development, one-time restructuring and related items in connection with acquisitions, investments and divestitures, non-recurring consulting fees, certain litigation expenses and settlements, certain European medical device regulation costs, gains and losses from strategic investments, and non-cash interest expense (excluding debt issuance cost). Management also uses certain non-GAAP measures which are intended to exclude the impact of foreign exchange currency fluctuations. The measure constant currency utilizes an exchange rate that eliminates fluctuations when calculating financial performance numbers. The Company also uses measures such as free cash flow, which represents cash flow from operations less cash used in the acquisition and disposition of capital. Additionally, the Company uses an adjusted EBITDA measure which represents earnings before interest, taxes, depreciation and amortization and excludes the impact of stock-based compensation, business transition costs, purchased in-process research and development, one-time restructuring and related items in connection with acquisitions, investments and divestitures, non-recurring consulting fees, certain litigation expenses and settlements, certain European medical device regulation costs, gains and losses on strategic investments, and other significant one-time items.

Management calculates the non-GAAP financial measures provided in this earnings release excluding these costs and uses these non-GAAP financial measures to enable it to further and more consistently analyze the period-to-period financial performance of its core business operations. Management believes that providing investors with these non-GAAP measures gives them additional information to enable them to assess, in the same way management assesses, the Company's current and future continuing operations. These non-GAAP measures are not in accordance with, or an alternative for, GAAP, and may be different from non-GAAP measures used by other companies. Set forth below are reconciliations of the non-GAAP financial measures to the comparable GAAP financial measure.

During the quarter ended June 30, 2018, the Company began excluding from its non-GAAP financial results certain litigation related expenses associated with ongoing litigation with a former Board member and his current employer related to various matters, including infringement of the Company's intellectual property. For consistency and comparability, the Company has re-casted non-GAAP financial results for each of the quarters ended Dec. 31, 2017 and March 31, 2018 to exclude these litigation expenses in such periods, which were $0.4 million and $0.6 million, respectively.

For the Three Months Ended March 31, 2019

Reconciliation of GAAP to Non-GAAP Financial Measures

(Unaudited - in thousands, except per share data)









Gross
Profit

Operating
Profit

Net
Income 

Diluted
EPS

Diluted
WASO 5

Net Income
to Adjusted
EBITDA

Reported GAAP

$      200,282

$         20,173

$         9,386

$   0.18

52,480

$                       9,386

% of revenue

72.9%

7.3%





Amortization of intangible assets


13,625

13,625




Litigation related expenses and settlements1


3,046

3,046



3,046

Business transition costs2


3,833

3,833



3,833

European medical device regulation3


332

332



332

Non-cash interest expense on convertible notes



4,319




Tax effect of adjustments 4



(6,933)




Interest expense/(income), net






9,104

Income tax expense






1,317

Depreciation and amortization






34,054

Non-cash stock based compensation






5,717

Adjusted Non-GAAP

$      200,282

$         41,009

$       27,608

$   0.53

52,480

$                     66,789

% of revenue

72.9%

14.9%




24.3%



1

Represents expenses associated with ongoing litigation with a former Board member and his current employer related to various matters, including infringement of the Company's intellectual property.

2

Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party merger and acquisitions costs, contingent consideration fair value adjustments, and other costs directly associated with such activities.

3

Represents costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with European medical device regulation.

4

Represents the impact from tax affecting the adjustments above at their statutory tax rate. As of May 1, 2019, the Company estimated an annual tax rate of ~22% on a GAAP basis and ~23% on a non-GAAP basis.

5

Adjusted non-GAAP diluted WASO excludes the impact of dilutive convertible notes and warrants for which the Company is economically hedged through its anti-dilutive bond hedge arrangements.

 

For the Three Months Ended March 31, 2018

Reconciliation of GAAP to Non-GAAP Financial Measures

(Unaudited - in thousands, except per share data)









Gross
Profit

Operating
Profit
(Loss)

Net Income
(Loss)

Diluted
EPS

Diluted
WASO 6

Net Income
(Loss) to
Adjusted
EBITDA

Reported GAAP

$      186,708

$       (18,222)

$      (27,132)

$ (0.53)

51,226

$                   (27,132)

% of revenue

71.7%

(7.0%)





Non-cash purchase accounting adjustments on acquisitions 1

405

405

405



405

Non-recurring consulting fees 2


6,084

6,084



6,084

Amortization of intangible assets


12,425

12,425




Litigation related expenses and settlements 3


29,586

29,586



29,586

Business transition costs 4


2,253

2,253



2,253

Non-cash interest expense on convertible notes



4,099




Net loss on strategic investments



9,004



9,004

Tax effect of adjustments 5



(16,109)




Interest expense/(income), net






9,333

Income tax benefit






(10,126)

Depreciation and amortization






32,090

Non-cash stock based compensation






4,134

Adjusted Non-GAAP

$      187,113

$         32,531

$       20,615

$   0.40

51,742

$                     55,631

% of revenue

71.8%

12.5%




21.4%



1

Represents costs associated with non-cash purchase accounting adjustments, such as acquired inventory fair market value adjustments, which are amortized over the period in which underlying products are sold.

2

Non-recurring consulting fees associated with the implementation of our state tax-planning strategy.

3

Represents the loss recorded in connection with the settlement of the Madsen Medical, Inc. litigation matter, as well as expenses associated with ongoing litigation with a former Board member and his current employer related to various matters, including infringement of the Company's intellectual property.

4

Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party merger and acquisitions costs, contingent consideration fair value adjustments, and other costs directly associated with such activities.

5

Represents the impact from tax affecting the adjustments above at their statutory tax rate. As of May 1, 2018, the Company estimated an annual tax rate of ~31% on a GAAP basis and ~23% on a non-GAAP basis.

6

Adjusted non-GAAP diluted WASO excludes the impact of dilutive convertible notes and warrants for which the Company is economically hedged through its anti-dilutive bond hedge arrangements.

Investor Conference Call
NuVasive will hold a conference call today at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results of its financial performance for the first quarter 2019. The dial-in numbers are 1-877-407-9039 for domestic callers and 1-201-689-8470 for international callers. A live webcast of the conference call will be available online from the Investor Relations page of the Company's website at www.nuvasive.com. After the live webcast, the call will remain available on NuVasive's website through May 31, 2019. In addition, a telephone replay of the call will be available until May 8, 2019. The replay dial-in numbers are 1-844-512-2921 for domestic callers and 1-412-317-6671 for international callers. Please use pin number: 13689332.

About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company's portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With more than $1 billion in revenues, NuVasive has approximately 2,600 employees and operates in more than 50 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.

Forward-Looking Statements
NuVasive cautions you that statements included in this news release or made on the investor conference call referenced herein that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward looking statements. In addition, this news release contains selected financial results from the first quarter 2019, as well as projections for 2019 financial guidance and longer-term financial performance goals. The Company's results for the first quarter 2019 are prior to the completion of review and audit procedures by the Company's external auditors and are subject to adjustment. In addition, the Company's projections for 2019 financial guidance and longer-term financial performance goals represent initial estimates, and are subject to the risk of being inaccurate because of the preliminary nature of the forecasts, the risk of further adjustment, or unanticipated difficulty in selling products or generating expected profitability. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products (including the iGA® platform), the Company's ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties more fully described in the Company's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

NuVasive, Inc. 

Consolidated Statements of Operations 

(in thousands, except per share data)








Three Months Ended March 31,

(unaudited)


2019


2018

Revenue





Product revenue


$ 243,823


$ 233,515

Service revenue


30,953


27,007

Total revenue


274,776


260,522

Cost of revenue (excluding below amortization of intangible assets)





Cost of products sold 


54,486


55,191

Cost of services


20,008


18,623

Total cost of revenue


74,494


73,814

Gross profit


200,282


186,708

Operating expenses:





Sales, marketing and administrative


145,076


146,766

Research and development


17,575


14,491

Amortization of intangible assets


13,625


12,425

Litigation liability loss



28,995

Business transition costs


3,833


2,253

Total operating expenses


180,109


204,930

Interest and other expense, net:





Interest income


409


134

Interest expense


(9,513)


(9,467)

Other (expense) income, net


(366)


(9,703)

Total interest and other expense, net


(9,470)


(19,036)

Income (loss) before income taxes


10,703


(37,258)

Income tax (expense) benefit


(1,317)


10,126

Consolidated net income (loss)


$     9,386


$ (27,132)






Net income (loss) per share:





Basic


$       0.18


$     (0.53)

Diluted


$       0.18


$     (0.53)

Weighted average shares outstanding:





Basic


51,675


51,226

Diluted


52,480


51,226

 

NuVasive, Inc. 

Consolidated Balance Sheets 

(in thousands, except par values and share amounts) 








March 31, 2019


December 31, 2018

ASSETS


(unaudited)



Current assets:





Cash and cash equivalents


$            93,391


$                117,840

Accounts receivable, net of allowances of $16,125 and $16,171, respectively


194,358


196,487

Inventory, net


288,539


273,244

Prepaid income taxes


16,484


16,905

Prepaid expenses and other current assets


13,555


13,733

Total current assets


606,327


618,209

Property and equipment, net


247,533


238,841

Intangible assets, net


240,663


252,048

Goodwill


561,235


561,366

Operating lease right-of-use assets


61,400


Deferred tax assets


4,369


5,263

Restricted cash and investments


2,395


2,395

Other assets


27,180


29,737

Total assets


$       1,751,102


$             1,707,859

LIABILITIES AND EQUITY





Current liabilities:





Accounts payable and accrued liabilities


$            99,991


$                105,877

Contingent consideration liabilities


6,637


7,560

Accrued payroll and related expenses


44,824


59,960

Operating lease liabilities


6,320


Litigation liabilities


2,045


1,415

Income tax liabilities


1,964


4,648

Total current liabilities


161,781


179,460

Senior convertible notes


607,607


602,526

Deferred and income tax liabilities


5,641


4,964

Operating lease liabilities


67,112


Other long-term liabilities


68,955


86,384

Commitments and contingencies





Stockholders' equity:





Preferred stock, $0.001 par value; 5,000,000 shares authorized, none outstanding



Common stock, $0.001 par value; 120,000,000 shares authorized at March 31, 2019 and December 31, 2018, 57,119,047 and 56,648,077 issued and outstanding at March 31, 2019 and December 31, 2018, respectively


61


61

Additional paid-in capital


1,402,797


1,397,829

Accumulated other comprehensive loss


(9,122)


(8,628)

Retained earnings


26,627


17,241

Treasury stock at cost; 5,262,478 shares and 5,116,496 shares at March 31, 2019 and December 31, 2018, respectively


(580,357)


(571,978)

Total equity


840,006


834,525

Total liabilities and equity


$       1,751,102


$             1,707,859

 

NuVasive, Inc. 

Consolidated Statements of Cash Flows 

(in thousands) 








Three Months Ended March 31,

(unaudited)


2019


2018

Operating activities:





Consolidated net income (loss)


$   9,386


$ (27,132)

Adjustments to reconcile net income (loss) to net cash provided by operating activities:





Depreciation and amortization


34,054


32,090

Impairment of strategic investment



9,003

Amortization of non-cash interest


5,210


4,925

Stock-based compensation


5,717


4,134

Reserves on current assets


3,785


4,080

Other non-cash adjustments


2,816


4,456

Deferred income taxes


1,547


(12,671)

Changes in operating assets and liabilities, net of effects from acquisitions:





Accounts receivable


1,620


16,933

Inventory


(19,292)


(12,126)

Prepaid expenses and other current assets


(1,399)


(1,737)

Accounts payable and accrued liabilities


(2,523)


1,579

Accrued payroll and related expenses


(14,815)


(18,493)

Litigation liability


630


30,040

Income taxes


(2,261)


1,294

Net cash provided by operating activities


24,475


36,375

Investing activities:





Acquisitions and investments



(51,794)

Purchases of intangible assets


(6,827)


(2,657)

Purchases of property and equipment


(33,929)


(29,109)

Net cash used in investing activities


(40,756)


(83,560)

Financing activities:





Proceeds from the issuance of common stock



336

Purchases of treasury stock


(8,177)


(2,155)

Payment of contingent consideration


(1,435)


(8,900)

Proceeds from revolving line of credit



65,000

Repayments on revolving line of credit



(10,000)

Other financing activities


1,556


(141)

Net cash (used in) provided by financing activities


(8,056)


44,140

Effect of exchange rate changes on cash


(112)


982

Decrease in cash, cash equivalents and restricted cash


(24,449)


(2,063)

Cash, cash equivalents and restricted cash at beginning of period


120,235


78,198

Cash, cash equivalents and restricted cash at end of period


$ 95,786


$  76,135

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/nuvasive-announces-first-quarter-2019-financial-results-300842022.html

SOURCE NuVasive, Inc.

Investor & Media Contact: Suzanne Hatcher, NuVasive, Inc., 858-458-2240, investorrelations@nuvasive.com